Prostate Cancer

Prostate cancer is the most common cancer in men and affects 1 out of 7 men between the ages of 45 to 75 years of age. It is the second leading cause of cancer deaths in the United States after lung cancer. Prostate cancer can metastasize, or spread, to multiple organs, including the bones, lymph nodes, and lungs


How do we diagnose Prostate Cancer?

Magnetic Resonance (MR)

Prostate MR is a very powerful tool for diagnosing prostate cancer.  Currently, it is the most accurate noninvasive method to diagnose new cases of prostate cancer and can be used to direct prostate biopsies.   MRI does not use or produce radiation and is not associated with radiation risks or effects.

Bone Scan

bone scan is a very accurate test to detect any disease in the bones.  Prostate cancer can commonly spread to the bones (metastasize) and the bone scan is the most commonly used method to detect this type of disease.

Computed Tomography (CT)

CT is one of the most common ways to follow prostate cancer and detect spread (metastases). CT is very accurate to detect small metastatic nodes or other diseases in the liver or bones.

Positron Emission Tomography (PET)/CT

PET/CT is an advanced method that can detect the spread (metastases) of prostate cancer. In cases of prostate cancer a special radiotracer, fluciclovine F-18, also known as Axumin is used in conjunction with a CT scan to show sites of disease. This technique is much more sensitive to finding metastases than CT alone.

How do we treat Prostate Cancer?

Prostate cancer is usually treated by a multidisciplinary team of physicians.  Radiologists treat bone metastases from prostate cancer with a noninvasive technique called Xofigo (radium 223 dichloride). This compound is taken up by bone cells and kills metastatic prostate cancer cells with a small targeted dose of radiation without damaging normal nearby cells. The goal of this treatment is to target metastases while avoiding the whole-body effects of radiation therapy or chemotherapy.